Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JYNT
stocks logo

JYNT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.29M
-55.28%
0.045
-125%
14.08M
+7.67%
0.150
+200%
14.69M
+10.68%
0.190
+1800%
Estimates Revision
The market is revising Downward the revenue expectations for The Joint Corp. (JYNT) for FY2025, with the revenue forecasts being adjusted by -0.86% over the past three months. During the same period, the stock price has changed by -20.58%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-15.62%
In Past 3 Month
Stock Price
Go Down
down Image
-20.58%
In Past 3 Month
Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 8.450
sliders
Low
9.00
Averages
11.33
High
14.00
Current: 8.450
sliders
Low
9.00
Averages
11.33
High
14.00
B. Riley
B. Riley
Buy -> Neutral
downgrade
$18 -> $9
2025-11-07
Reason
B. Riley
B. Riley
Price Target
$18 -> $9
2025-11-07
downgrade
Buy -> Neutral
Reason
B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.
Lake Street
Ryan Meyers
Buy
downgrade
$16 -> $11
2025-11-07
Reason
Lake Street
Ryan Meyers
Price Target
$16 -> $11
2025-11-07
downgrade
Buy
Reason
Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $11 from $16 and keeps a Buy rating on the shares. The transition toward a fully franchised model has taken longer than originally expected, says the analyst, who lowers the firm's price target as the underlying fundamentals at the clinic level remain soft.
Roth Capital
Buy
maintain
$15 -> $14
2025-11-07
Reason
Roth Capital
Price Target
$15 -> $14
2025-11-07
maintain
Buy
Reason
Roth Capital lowered the firm's price target on Joint Corp. to $14 from $15 and keeps a Buy rating on the shares after its Q3 results. Refranchising process continues to progress, albeit slowly, but the firm remains confident that margin and free cash flow will inflect higher upon completion, the analyst tells investors in a research note.
Lake Street
Ryan Meyers
Buy
downgrade
$20 -> $16
2025-05-09
Reason
Lake Street
Ryan Meyers
Price Target
$20 -> $16
2025-05-09
downgrade
Buy
Reason
Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $16 from $20 and keeps a Buy rating on the shares. The firm believes The Joint continues to make positive strides in its corporate clinic transition following its first quarter 2025 results, but is trimming its price target based on a lower 2026 EBITDA estimate.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Joint Corp (JYNT.O) is 14.96, compared to its 5-year average forward P/E of 113.09. For a more detailed relative valuation and DCF analysis to assess Joint Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
113.09
Current PE
14.96
Overvalued PE
210.87
Undervalued PE
15.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
28.45
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
52.08
Undervalued EV/EBITDA
4.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.06
Current PS
0.00
Overvalued PS
8.00
Undervalued PS
0.12
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

JYNT News & Events

Events Timeline

(ET)
2025-11-06
17:01:00
Joint Corp. unveils new $12M stock buyback initiative
select
2025-11-06
17:00:15
Joint Corp. supports FY25 adjusted EBITDA forecast of $10.8M-$11.8M
select
2025-11-06
16:58:37
Joint Corp. announces Q3 earnings per share of 6 cents, surpassing consensus of 0 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
02:00 AMNASDAQ.COM
Insider Buying Update for Thursday, December 4: DMLP, JYNT

  • Dorchester Minerals Insider Purchase: Director Frank Damon Box bought 5,000 shares of DMLP at $21.96 each, totaling $109,825, and is currently up 2.9% based on recent trading highs.

  • Joint Insider Purchase: Charles E. Jobson purchased 13,000 shares of Joint for $8.41 each, amounting to $109,330, with a slight increase of 0.2% in trading on Thursday.

  • Previous Purchases: Box had previously bought shares worth $102,276 at $25.57 each, while Jobson's earlier purchase was for $141,668 at $8.45 each.

  • Market Performance: Dorchester Minerals is up 1.1% on Thursday, reflecting positive market activity for both companies involved.

[object Object]
Preview
5.0
11-18Newsfilter
Take Care of Your Back This Holiday with The Joint Chiropractic's "Back Friday Offers"

  • Holiday Chiropractic Offer: The Joint Chiropractic is launching its annual "Back Friday" campaign from Nov. 17 to Dec. 8, offering additional chiropractic visits with the purchase of visit packages to help alleviate holiday-related back stress.

  • Benefits of Chiropractic Care: Chiropractic adjustments can help reduce stress headaches, muscle tension, and fatigue, providing a natural energy boost and improved mobility during the demanding holiday season.

  • Convenient Care Model: The Joint Chiropractic operates with a no-appointments, no-insurance hassle model, making chiropractic care accessible and affordable for a wide range of patients, including children, athletes, and seniors.

  • Industry Leadership: The Joint Corp. is the largest operator of chiropractic clinics in the U.S., recognized for its innovative retail healthcare model and consistently ranked among top franchises in the chiropractic industry.

[object Object]
Preview
9.5
11-07NASDAQ.COM
The Joint Corp. (JYNT) Surpasses Q3 Earnings and Revenue Projections

  • Earnings Performance: The Joint Corp. (JYNT) reported quarterly earnings of $0.02 per share, exceeding expectations of a loss, and showing a significant earnings surprise of +300.00%. However, revenues of $13.38 million were down from $30.2 million year-over-year.

  • Stock Outlook: Despite outperforming earnings estimates in two of the last four quarters, The Joint's shares have declined by 22% this year, contrasting with the S&P 500's 15.6% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Future Earnings Estimates: The consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $15.04 million, while the fiscal year estimate is $0.03 on $54.63 million in revenues. The outlook for the Medical - HMOs industry, where The Joint operates, is currently weak, ranking in the bottom 27% of Zacks industries.

  • Comparative Analysis: Health Catalyst (HCAT), another company in the medical sector, is set to report its earnings soon, with expectations of a decline in both EPS and revenues. Investors are encouraged to consider industry trends and earnings estimate revisions when evaluating stock performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Joint Corp (JYNT) stock price today?

The current price of JYNT is 8.45 USD — it has increased 0.84 % in the last trading day.

arrow icon

What is Joint Corp (JYNT)'s business?

The Joint Corp. is a franchisor and operator of chiropractic clinics that uses a private pay, non-insurance, cash-based model. The Company operates the Franchise Operations segment. The Company and its franchisees provide management services to affiliate professional chiropractic practices. The franchise system consists of approximately 811 clinics in operation. It offers a range of membership and wellness packages. It offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.

arrow icon

What is the price predicton of JYNT Stock?

Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Joint Corp (JYNT)'s revenue for the last quarter?

Joint Corp revenue for the last quarter amounts to 13.38M USD, increased 5.74 % YoY.

arrow icon

What is Joint Corp (JYNT)'s earnings per share (EPS) for the last quarter?

Joint Corp. EPS for the last quarter amounts to 0.06 USD, decreased -128.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Joint Corp (JYNT)'s fundamentals?

The market is revising Downward the revenue expectations for The Joint Corp. (JYNT) for FY2025, with the revenue forecasts being adjusted by -0.86% over the past three months. During the same period, the stock price has changed by -20.58%.
arrow icon

How many employees does Joint Corp (JYNT). have?

Joint Corp (JYNT) has 443 emplpoyees as of December 05 2025.

arrow icon

What is Joint Corp (JYNT) market cap?

Today JYNT has the market capitalization of 125.47M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free